Higher mortality risk from lung and hematological neoplasms in patients with rheumatoid arthritis: An observational study from the Spanish National Registry
Fecha:
2024Palabra clave:
Revista / editorial:
Medicina ClínicaCitación:
Esteban-Sampedro, J., Moreno-Torres, V., & Martín-Portugués, M. (2025). Higher mortality risk from lung and hematological neoplasms in patients with rheumatoid arthritis: An observational study from the Spanish National Registry. Medicina clinica, 164(2), 69–72. https://doi.org/10.1016/j.medcli.2024.09.007Tipo de Ítem:
article
Resumen:
Objective: Evaluating the impact of solid organ neoplasms (SON) and hematological neoplasms (HN) on mortality among RA patients in a nationwide study.
Methods: A retrospective, observational comparison of SON and HN-related deaths in RA patients and the general Spanish population was conducted (Spanish Hospital Discharge Database). Binary logistic regression analyzed the impact of RA on mortality risk from each neoplasm.
Results: From 2016 to 2019, 139,531 neoplasm-related deaths were recorded, including 813 (0.6%) from RA patients. Patients with RA presented a lower mortality rate from SON (85.1% vs 91.2%, OR 0.99), mainly due to colorectal carcinoma (8% vs 10.6%, OR 0.67) and hepatocarcinoma (1% vs 2.7%, OR 0.44), but higher lung neoplasms risk (20.2% vs 18.6%, OR 1.31). HN-related deaths were also more prevalent in RA patients (14.9% vs 8.8%, OR 1.73), especially B and T/NK non-Hodgkin's lymphoma (6% vs 2.8%, OR 2.12) and myeloid leukemia (4.4% vs 2.3%, OR 1.92).
Conclusion: RA patients might have a higher mortality risk from lung and hematologic neoplasms. Reducing immunosuppressive burden and developing early-detection programs should be primary goals in this population.
Descripción:
Objetivos
Evaluar el impacto de neoplasias de órgano sólido (NOS) y hematológicas (NH) en la mortalidad de pacientes con AR a nivel nacional.
Métodos
Estudio observacional retrospectivo comparativo de muertes por NOS y NH en pacientes con AR versus población general española (Registro de Actividad de Atención Especializada). Se evaluó el impacto de la AR en cada neoplasia mediante regresión logística binaria.
Resultados
Entre 2016 y 2019, se registraron 139.531 muertes por neoplasias, 813 (0,6%) en pacientes con AR. Los pacientes con AR mostraron menor mortalidad por NOS (85,1% vs. 91,2%, OR 0,99), especialmente carcinoma colorrectal (8% vs. 10,6%, OR 0,67) y hepatocarcinoma (1% vs. 2,7%, OR 0,44), pero mayor riesgo de neoplasia pulmonar (20,2% vs. 18,6%, OR 1,31). Las muertes por NH fueron más frecuentes en AR (14,9% vs. 8,8%, OR 1,73), especialmente linfomas no Hodgkin B y T/NK (6% vs. 2,8%, OR 2,12) y leucemia mieloide (4,4% vs. 2,3%, OR 1,92).
Conclusión
Los pacientes con AR podrían tener un mayor riesgo de mortalidad por neoplasias pulmonares y hematológicas. La reducción de la carga inmunosupresora y el desarrollo de programas de detección temprana deben ser objetivos clave en esta población.
Ficheros en el ítem
Nombre: 63. Higher mortality risk from lung and hematological neoplasms in patients with rheumatoid arthritis- An observational study from the Spanish National Registry.pdf
Tamaño: 337.8Kb
Formato: application/pdf
